The North America Molecular Diagnostics Market is expected to reach $18.13 billion by 2030 at a CAGR of 5.3% from 2023 to 2030. Molecular diagnostics help detect the targeted genetic material in human, viral, and bacterial genomes. Molecular diagnostic tests are increasingly being used in many areas, including testing infectious diseases, oncology, and clinical genetics. Advancements in molecular diagnostics will continue to improve the accuracy and speed of diagnosis and will become an essential aspect of patient-tailored interventions and therapeutics. Polymerase chain reaction (PCR) and microarray technology offer high throughput and more accurate tests. Additionally, sequencing has emerged as an alternative molecular diagnostic technology with diverse applications.
The growth of the North America molecular diagnostics market is driven by several factors, including the rising geriatric population, the increasing prevalence of communicable & non-communicable diseases, technological advancements in molecular diagnostics, and rising healthcare expenditures. However, unfavorable regulatory frameworks and the high costs of molecular diagnostic tests restrain the growth of this market.
Furthermore, increasing focus on companion diagnostics and the rising popularity of direct-to-consumer (DTC) genetic testing are expected to create growth opportunities for the players in this market. However, the shortage of skilled professionals is a major challenge for market growth. Additionally, the rising integration of artificial intelligence & machine learning is a prominent trend in the molecular diagnostics market.
Click here to: Get Free Sample Pages of this Report
The healthcare landscape is constantly changing due to innovations in medical technologies. In recent years, companies have focused on developing advanced diagnostic kits that yield faster results than traditional kits. These advanced kits allow healthcare providers and caregivers to make crucial medical decisions promptly. For instance, companies have been developing ultra-fast PCR kits to minimize the time required to generate test results.
Moreover, traditional PCR tests have transitioned to incorporate multiplex capabilities, including simultaneously detecting two or more pathogens. Multiplex diagnostic tests provide higher accuracy for critical care, which leads to pathogen-specific treatment. Also, the CLIA-waived molecular PoC platform is widely accepted, as traditional POC tests lack sensitivity.
Traditional tests can be replaced by rapid molecular diagnostic tests that are simple, easy to use, and highly accurate. Market players are launching PoC molecular PCR tests. For instance, in June 2021, Thermo Fisher Scientific (U.S.) developed the innovative and portable Accula SARS-CoV-2 Test offering gold-standard Reverse Transcription Polymerase Chain Reaction (RT-PCR) detection of SARS-CoV-2 in a point-of-care format. The test delivers results in 30 minutes, whereas the conventional RT PCR method takes around 2–3 days to produce results. The product uses a cartridge (lateral flow technology) that can be directly used to analyze samples, unlike conventional RT PCR tests, where nucleic acid extraction takes a significant amount of time.
Increasing Focus on Companion Diagnostics is Providing Opportunity for Market Growth
Companion molecular diagnostics measure the levels of proteins, genes, or specific mutations to reveal specific and effective therapies for an individual’s condition. Companion diagnostics (CDx) are a form of personalized, stratified, and precision medicine that individualizes a patient’s treatment. CDx has expanded from oncology drugs to multiple therapeutic areas, and the number of combinations has grown significantly over the years.
Furthermore, personalized medicine for infectious diseases helps to orient the molecular management of infections. Molecular microbiology offers technologies that can detect and identify microorganisms rapidly. Determining the pharmacogenetic profiles of patients suffering from infectious diseases provides an additional assessment of the drug metabolizer phenotype or the risk of potential adverse drug interactions. Personalized medicine is thus expected to develop new therapies and new methods for disease detection.
Companies in this market are collaborating for the development and commercialization of CDx due to the growth potential of companion diagnostics. For instance, in September 2021, Illumina, Inc. (U.S.) and Merck KGaA (Germany) partnered to develop and commercialize companion diagnostic tests to identify genetic mutations in patients with HRD-positive tumors who are eligible for the PARP inhibitor targeted treatment.
In 2023, the Kits & Reagents Segment is Expected to Dominate this Market
Based on product & service, the North America molecular diagnostics market is segmented into kits & reagents, instruments, and software & services. In 2023, the kits & reagents segment is expected to account for the largest share of the market. The large market share of this segment is attributed to factors such as the commercial availability of a diverse range of diagnostic reagents & consumables, the availability of disease-specific test kits & assays, growing awareness regarding early disease diagnosis, and the outbreak of COVID-19. Moreover, the emergence of various POC tests and assays is creating significant opportunities for suppliers of molecular diagnostic kits & reagents.
Sequencing Technology Segment is Expected to Grow at Highest CAGR During Forecast Period
Based on technology, the North America molecular diagnostics market is segmented into polymerase chain reaction (PCR), in situ hybridization (ISH), isothermal nucleic acid amplification technology (INAAT), microarrays, mass spectrometry, sequencing, and other technologies. The sequencing segment is expected to register the highest CAGR during the forecast period. The growth of this segment is attributed to the advantages of sequencing, including the detection of low-frequency variants with higher sensitivity rates, comprehensive genomic coverage, detection at a lower limit of samples, and simultaneous sequencing of multiple genes or gene regions. In January 2020, the Centers for Medicare & Medicaid Services (CMS) approved the use of Medicare coverage of next-generation sequencing tests for inherited ovarian and breast cancers, expanding the coverage of NGS as a diagnostic tool in the U.S.
In 2023, the Laboratory Test Segment is Estimated to Account for the Largest Share of the Market
Based on test type, the North America molecular diagnostics market is segmented into laboratory tests and PoC tests. In 2023, the laboratory tests segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the wide availability of laboratory tests in hospitals, diagnostic laboratories, academic institutions, and research centers. Furthermore, laboratory tests are often the preferred choice among patients for diagnostic purposes. Companies’ efforts to launch new solutions for laboratory tests also contribute to the segment’s growth. For instance, in June 2022, Becton, Dickinson and Company (U.S.) launched its BD MAX Respiratory Viral Panel (RVP) assay for the BD MAX System. This RT-PCR assay is a combination test for SARS-CoV-2, Influenza A + B, and Respiratory Syncytial Virus (RSV).
The Oncology Segment is Expected to Grow at Highest CAGR During Forecast Period
Based on application, the North America molecular diagnostics market is segmented into infectious diseases, oncology, genetic testing, neurological diseases, cardiovascular diseases, and other applications. The oncology segment is expected to register the highest CAGR during the forecast period. The increasing prevalence of cancer, the rising mortality rate, and the need for early diagnosis drive the segment’s growth. In the U.S., the overall number of cancer cases is estimated to reach 2,727,182 in 2030 from 2,281,658 in 2020. (Source: GLOBOCAN). The product approval for the oncology molecular diagnostic tests also supports the market growth. For instance, in October 2020, F. Hoffmann-La Roche Ltd (Switzerland) received U.S. Food and Drug Administration (FDA) approval for the cobas EGFR Mutation Test v2. This real-time PCR test is used to qualitatively detect EGFR gene mutations in non-small cell lung cancer (NSCLC) patients.
In 2023, the Hospitals & Clinics Segment is Expected to Dominate this Market
Based on end user, the North America molecular diagnostics market is segmented into hospitals & clinics, diagnostic laboratories, academic & research institutes, and other end users. In 2023, the hospitals & clinics segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the increased number of hospitalizations due to various diseases requiring molecular diagnosis and the proliferation of hospitals and clinics in emerging countries, leading to growth in the utilization of molecular diagnostic products. For instance, in 2021, hospital expenditures in the U.S. grew by 4.4% compared to 2020, reaching USD 1,323.9 billion.
U.S.: Fastest Growing Market
The U.S. is expected to register the highest CAGR during the forecast period. The market growth in the U.S. is attributed to the large number of laboratory tests performed annually in the country, the country’s highly developed healthcare infrastructure, the rising prevalence of chronic diseases, the aging population, and the presence of large diagnostics companies. For instance, according to the American Association for Clinical Chemistry, around 13 billion laboratory tests are performed annually in the U.S. Moreover, the demand for molecular diagnostics has increased significantly since the emergence of the COVID-19 pandemic.
Key Players
The report provides a comprehensive competitive landscape analysis based on the product offerings and geographical presence of prominent market players. It also highlights key growth strategies adopted by these leading companies between 2020 and 2023. The key players operating in the North America molecular diagnostics market are Hologic, Inc. (U.S.), Danaher Corporation (U.S.), BioMérieux S.A. (France), Becton, Dickinson and Company (U.S.), Siemens Healthineers AG (Germany), DiaSorin S.p.A. (Italy), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), F. Hoffmann-La Roche (Switzerland), QIAGEN N.V. (Netherlands), and Seegene, Inc. (South Korea).
Scope of the Report:
North America Molecular Diagnostics Market Assessment, by Product & Service
North America Molecular Diagnostics Market Assessment, by Test Type
North America Molecular Diagnostics Market Assessment, by Technology
North America Molecular Diagnostics Market Assessment, by Application
North America Molecular Diagnostics Market Assessment, by End User
North America Molecular Diagnostics Market Assessment, by Country
Key questions answered in the report:
The North America Molecular Diagnostics Market study covers the market sizes & forecasts for various molecular diagnostics products used in the healthcare sector. The report involves the value analysis of various segments and subsegments of the molecular diagnostics market at the country level.
The North America Molecular Diagnostics Market is projected to reach $18.13 billion by 2030 at a CAGR of 5.3% from 2023 to 2030.
Based on product & service, in 2023, the reagents/kits segment is expected to account for the largest share of the North America Molecular Diagnostics Market. This segment is also projected to register the highest CAGR during the forecast period. The growth of this segment is driven by the increased demand for kits due to the growing prevalence of diseases and the growing awareness of early diagnosis.
The diagnostic laboratories segment is slated to register the highest CAGR during the forecast period. The growth of this segment is driven by the rising number of diagnostic laboratories and the increasing installation of advanced systems in laboratories.
The growth of the North America Molecular Diagnostics Market is driven by several factors, including the rising geriatric population, the increasing prevalence of communicable & non-communicable diseases, technological advancements in molecular diagnostics, and rising healthcare expenditures. Furthermore, increasing focus on companion diagnostics and the rising popularity of direct-to-consumer (DTC) genetic testing are expected to create growth opportunities for the players in this market.
The key players operating in the North America Molecular Diagnostics Market are Hologic, Inc. (U.S.), Danaher Corporation (U.S.), BioMérieux S.A. (France), Becton, Dickinson and Company (U.S.), Siemens Healthineers AG (Germany), DiaSorin S.p.A. (Italy), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), F. Hoffmann-La Roche (Switzerland), QIAGEN N.V. (Netherlands), and Seegene, Inc. (South Korea).
The U.S. is expected to offer significant growth opportunities due to the high number of laboratory tests performed annually in the country, the country’s highly developed healthcare infrastructure, the rising prevalence of chronic diseases, the aging population, and the presence of large diagnostics companies.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Technological Advancements in Molecular Diagnostics
4.2.2. Increasing use of PoC Diagnostic Tests
4.2.3. Increase in Focus and Funding for R&D of Diagnostic Products
4.2.4. Rising Geriatric Population
4.2.5. Rising Prevalence of Communicable and Non-communicable Diseases
4.3. Restraints
4.3.1. Unfavorable Regulatory Framework
4.3.2. High Cost of Molecular Diagnostic Tests
4.4. Opportunities
4.4.1. Companion Diagnostics to Offer New Growth Potential
4.4.2. Rising Popularity of Direct-To-Consumer (DTC) Genetic Testing
4.5. Challenges
4.5.1. Dearth of Skilled Professionals
4.6. Factor Analysis
4.7. Trends
4.8. Regulatory Analysis
4.9. Pricing Analysis
4.10. Porter’s 5 Force Analysis
5. North America Molecular Diagnostics Market Assessment — by Product & Service
5.1. Overview
5.2. Reagents & Kits
5.3. Instruments/Systems
5.4. Software & Services
6. North America Molecular Diagnostics Market Assessment — by Test Type
6.1. Overview
6.2. Lab Tests
6.3. PoC Tests
7. North America Molecular Diagnostics Market Assessment — by Technology
7.1. Overview
7.2. Polymerase Chain Reaction (PCR)
7.3. In Situ Hybridization (ISH)
7.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
7.5. Microarrays
7.6. Sequencing
7.7. Mass Spectrometry
7.8. Other Technologies
8. North America Molecular Diagnostics Market Assessment — by Application
8.1. Overview
8.2. Infectious Diseases
8.2.1. COVID-19
8.2.2. Hepatitis
8.2.3. HIV
8.2.4. Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG)
8.2.5. Human papillomavirus (HPV)
8.2.6. Tuberculosis
8.2.7. Influenza
8.2.8. Healthcare-associated Infections (HAIs)
8.2.9. Other Infectious Diseases
8.3. Oncology
8.3.1. Breast Cancer
8.3.2. Colorectal Cancer
8.3.3. Lung Cancer
8.3.4. Prostate Cancer
8.3.5. Lymphoma
8.3.6. Leukemia
8.3.7. Cervical Cancer
8.3.8. Other Cancer Types
8.4. Genetic Testing
8.5. Neurological Diseases
8.6. Cardiovascular Diseases
8.7. Other Applications
9. North America Molecular Diagnostics Market Assessment — by End User
9.1. Overview
9.2. Hospitals & Clinics
9.3. Diagnostic Laboratories
9.4. Academic & Research Institutes
9.5. Other End Users
10. North America Molecular Diagnostics Market Assessment — by Geography
10.1. Overview
10.2. U.S.
10.3. Canada
11. Competition Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share Analysis/Market Ranking, by Key Players (2022)
12. Company Profiles (Company Overview, Financial Snapshot, Product Portfolio, and Strategic Developments)
12.1. Hologic, Inc.
12.2. Danaher Corporation
12.3. BioMérieux S.A.
12.4. Becton, Dickinson and Company
12.5. Siemens Healthineers AG
12.6. DiaSorin S.p.A.
12.7. Abbott Laboratories
12.8. Thermo Fisher Scientific Inc.
12.9. Agilent Technologies, Inc.
12.10. Illumina, Inc.
12.11. F. Hoffmann-La Roche
12.12. QIAGEN N.V.
12.13. Seegene, Inc.
(Note: SWOT analysis is provided for the top 5 companies.)
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 North America Molecular Diagnostics Market Size, by Product & Service, 2021–2030 (USD Million)
Table 2 North America Molecular Diagnostics Reagents & Kits Market Size, by Country, 2021–2030 (USD Million)
Table 3 North America Molecular Diagnostics Instruments/Systems Market Size, by Country, 2021–2030 (USD Million)
Table 4 North America Molecular Diagnostics Software & Services Market Size, by Country, 2021–2030 (USD Million)
Table 5 North America Molecular Diagnostics Market Size, by Test Type, 2021–2030 (USD Million)
Table 6 North America Molecular Diagnostics for Lab Tests, by Country, 2021–2030 (USD Million)
Table 7 North America Molecular Diagnostics for PoC Tests, by Country, 2021–2030 (USD Million)
Table 8 North America Molecular Diagnostics Market Size, by Technology, 2021–2030 (USD Million)
Table 9 North America Molecular Diagnostics for Polymerase Chain Reaction (PCR), by Country, 2021–2030 (USD Million)
Table 10 North America Molecular Diagnostics for In Situ Hybridization (ISH), by Country, 2021–2030 (USD Million)
Table 11 North America Molecular Diagnostics for Isothermal Nucleic Acid Amplification Technology (INAAT), by Country, 2021–2030 (USD Million)
Table 12 North America Molecular Diagnostics for Chips and Microarrays, by Country, 2021–2030 (USD Million)
Table 13 North America Molecular Diagnostics for Mass Spectrometry, by Country, 2021–2030 (USD Million)
Table 14 North America Molecular Diagnostics for Sequencing, by Country, 2021–2030 (USD Million)
Table 15 North America Molecular Diagnostics for Transcription Mediated Amplification (TMA), by Country, 2021–2030 (USD Million)
Table 16 North America Molecular Diagnostics Market Size for Other Technologies, by Country, 2021–2030 (USD Million)
Table 17 North America Molecular Diagnostics Market Size, by Application, 2021–2030 (USD Million)
Table 18 North America Molecular Diagnostics Market Size for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 19 North America Molecular Diagnostics Market Size for Infectious Diseases Market Size, by Country, 2021–2030 (USD Million)
Table 20 North America Molecular Diagnostics Market Size for Hepatitis, by Country, 2021–2030 (USD Million)
Table 21 North America Molecular Diagnostics Market Size for HIV, by Country, 2021–2030 (USD Million)
Table 22 North America Molecular Diagnostics Market Size for Healthcare-associated Infections (HAIs), by Country, 2021–2030 (USD Million)
Table 23 North America Molecular Diagnostics Market Size for Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG), by Country, 2021–2030 (USD Million)
Table 24 North America Molecular Diagnostics Market Size for Human papillomavirus (HPV), by Country, 2021–2030 (USD Million)
Table 25 North America Molecular Diagnostics Market Size for Tuberculosis, by Country, 2021–2030 (USD Million)
Table 26 North America Molecular Diagnostics Market Size for Influenza, by Country, 2021–2030 (USD Million)
Table 27 North America Molecular Diagnostics Market Size for COVID-19, by Country, 2021–2030 (USD Million)
Table 28 North America Molecular Diagnostics Market Size for Other Infectious Diseases, by Country, 2021–2030 (USD Million)
Table 29 North America Molecular Diagnostics Market Size for Oncology, by Type, 2021–2030 (USD Million)
Table 30 North America Molecular Diagnostics Market Size for Oncology, by Country, 2021–2030 (USD Million)
Table 31 North America Molecular Diagnostics Market Size for Breast Cancer, by Country, 2021–2030 (USD Million)
Table 32 North America Molecular Diagnostics Market Size for Colorectal Cancer, by Country, 2021–2030 (USD Million)
Table 33 North America Molecular Diagnostics Market Size for Lung Cancer, by Country, 2021–2030 (USD Million)
Table 34 North America Molecular Diagnostics Market Size for Prostate Cancer, by Country, 2021–2030 (USD Million)
Table 35 North America Molecular Diagnostics Market Size for Lymphoma Cancer, by Country, 2021–2030 (USD Million)
Table 36 North America Molecular Diagnostics Market Size for Leukemia Cancer, by Country, 2021–2030 (USD Million)
Table 37 North America Molecular Diagnostics Market Size for Cervical Cancer, by Country, 2021–2030 (USD Million)
Table 38 North America Molecular Diagnostics Market Size for Other Cancer Types, by Country, 2021–2030 (USD Million)
Table 39 North America Molecular Diagnostics Market Size for Genetic Testing, by Country, 2021–2030 (USD Million)
Table 40 North America Molecular Diagnostics Market Size for Neurological Diseases, by Country, 2021–2030 (USD Million)
Table 41 North America Molecular Diagnostics Market Size for Other Applications, by Country, 2021–2030 (USD Million)
Table 42 North America Molecular Diagnostics Market Size, by End User, 2021–2030 (USD Million)
Table 43 North America Molecular Diagnostics Market Size for Hospitals & Clinics, by Country, 2021–2030 (USD Million)
Table 44 North America Molecular Diagnostics Market Size for Diagnostic Laboratories, by Country, 2021–2030 (USD Million)
Table 45 North America Molecular Diagnostics Market Size for Academic & Research Institutes, by Country, 2021–2030 (USD Million)
Table 46 North America Molecular Diagnostics Market Size for Other End Users, by Country, 2021–2030 (USD Million)
Table 47 North America: Molecular Diagnostics Market Size, by Country, 2021–2030 (USD Million)
Table 48 North America: Molecular Diagnostics Market Size, by Product, 2021–2030 (USD Million)
Table 49 North America: Molecular Diagnostics Market Size, by Test Type, 2021–2030 (USD Million)
Table 50 North America: Molecular Diagnostics Market Size, by Technology, 2021–2030 (USD Million)
Table 51 North America: Molecular Diagnostics Market Size, by Application, 2021–2030 (USD Million)
Table 52 North America: Molecular Diagnostics Market Size for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 53 North America: Molecular Diagnostics Market Size for Oncology, by Type, 2021–2030 (USD Million)
Table 54 North America: Molecular Diagnostics Market Size, by End User, 2021–2030 (USD Million)
Table 55 U.S.: Molecular Diagnostics Market Size, by Product, 2021–2030 (USD Million)
Table 56 U.S.: Molecular Diagnostics Market Size, by Test Type, 2021–2030 (USD Million)
Table 57 U.S.: Molecular Diagnostics Market Size, by Technology, 2021–2030 (USD Million)
Table 58 U.S.: Molecular Diagnostics Market Size, by Application, 2021–2030 (USD Million)
Table 59 U.S.: Molecular Diagnostics Market Size for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 60 U.S.: Molecular Diagnostics Market Size for Oncology, by Type, 2021–2030 (USD Million)
Table 61 U.S.: Molecular Diagnostics Market Size, by End User, 2021–2030 (USD Million)
Table 62 Canada: Molecular Diagnostics Market Size, by Product, 2021–2030 (USD Million)
Table 63 Canada: Molecular Diagnostics Market Size, by Test Type, 2021–2030 (USD Million)
Table 64 Canada: Molecular Diagnostics Market Size, by Technology, 2021–2030 (USD Million)
Table 65 Canada: Molecular Diagnostics Market Size, by Application, 2021–2030 (USD Million)
Table 66 Canada: Molecular Diagnostics Market Size for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 67 Canada: Molecular Diagnostics Market Size for Oncology, by Type, 2021–2030 (USD Million)
Table 68 Canada: Molecular Diagnostics Market Size, by End User, 2021–2030 (USD Million)
Table 69 Recent Developments, by Company, 2020–2023
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 North America Molecular Diagnostic Market Size, by Product, 2023 VS. 2030 (USD Million)
Figure 8 North America Molecular Diagnostic Market Size, by Test Type, 2023 VS. 2030 (USD Million)
Figure 9 North America Molecular Diagnostic Market Size, by Technology, 2023 VS. 2030 (USD Million)
Figure 10 North America Molecular Diagnostic Market Size, by Application, 2023 VS. 2030 (USD Million)
Figure 11 North America Molecular Diagnostic Market Size, by End User, 2023 VS. 2030 (USD Million)
Figure 12 North America Molecular Diagnostic Market, by Country
Figure 13 Market Dynamics
Figure 14 North America Molecular Diagnostics Market Size, by Product, 2023 VS. 2030 (USD Million)
Figure 15 North America Molecular Diagnostics Market Size, by Test Type, 2023 VS. 2030 (USD Million)
Figure 16 North America Molecular Diagnostics Market Size, by Technology, 2023 VS. 2030 (USD Million)
Figure 17 North America Molecular Diagnostics Market Size, by Application, 2023 VS. 2030 (USD Million)
Figure 18 North America Molecular Diagnostics Market Size, by End User, 2023 VS. 2030 (USD Million)
Figure 19 North America Molecular Diagnostics Market Size, by Country, 2023 VS. 2030 (USD Million)
Figure 20 North America: Molecular Diagnostics Market Snapshot
Figure 21 Key Growth Strategies Adopted by Leading Players, 2020–2023
Figure 22 North America Molecular Diagnostics Market: Competitive Benchmarking, by Product & Service
Figure 23 North America Molecular Diagnostics Market: Competitive Dashboard
Figure 24 North America Molecular Diagnostics Market: Market Share Analysis (2022)
Figure 25 Hologic, Inc.: Financial Overview (2022)
Figure 26 Danaher Corporation: Financial Overview (2022)
Figure 27 bioMérieux S.A.: Financial Overview (2022)
Figure 28 Becton, Dickinson and Company: Financial Overview (2022)
Figure 29 Siemens Healthineers AG: Financial Overview (2022)
Figure 30 DiaSorin S.p.A.: Financial Overview (2022)
Figure 31 Abbott Laboratories: Financial Overview (2022)
Figure 32 Thermo Fisher Scientific Inc.: Financial Overview (2022)
Figure 33 Agilent Technologies, Inc.: Financial Overview (2022)
Figure 34 Illumina, Inc.: Financial Overview (2022)
Figure 35 F. Hoffmann-La Roche: Financial Overview (2022)
Figure 36 QIAGEN N.V.: Financial Overview (2022)
Figure 37 Seegene, Inc.: Financial Overview (2022)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Jan-2024
Published Date: Nov-2023
Published Date: Nov-2023
Published Date: Jul-2023
